Debt to Equity Ratio Chart

View Debt to Equity Ratio for AMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 0.0118
March 31, 2026 0.0124
December 31, 2025 0.0132
September 30, 2025 0.0147
June 30, 2025 0.0158
March 31, 2025 0.0168
December 31, 2024 0.0159
September 30, 2024 0.0155
June 30, 2024 0.0147
March 31, 2024 0.0154
December 31, 2023 0.0158
September 30, 2023 0.0162
June 30, 2023 0.0166
March 31, 2023 0.0337
December 31, 2022 0.0337
September 30, 2022 0.0187
June 30, 2022 0.0193
March 31, 2022 0.0176
December 31, 2021 0.0155
September 30, 2021 0.0163
June 30, 2021 0.0163
March 31, 2021 0.0167
December 31, 2020 0.0156
September 30, 2020 0.033
June 30, 2020 0.0545
Date Value
March 31, 2020 0.0804
December 31, 2019 0.0985
September 30, 2019 0.1169
June 30, 2019 0.5223
March 31, 2019 0.5915
December 31, 2018 0.5275
September 30, 2018 -2.147
June 30, 2018 -2.507
March 31, 2018 -7.151
December 31, 2017 -1.884
September 30, 2017 -2.709
June 30, 2017 -3.288
March 31, 2017 -3.462
December 31, 2016 -12.86
September 30, 2016 7.735
June 30, 2016 -0.7577
March 31, 2016 -1.620
December 31, 2015 -1.959
September 30, 2015 -2.143
June 30, 2015 -2.597
March 31, 2015 -1.685
December 31, 2014 -2.648
September 30, 2014 -3.357
June 30, 2014 -4.347
March 31, 2014 -4.268

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 0.1088
Cellectis SA 2.539
Alkermes Plc 0.8695
Akari Therapeutics Plc 0.0373
Liquidia Corp. 0.9374